Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 369

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 369
---
 31,
2024
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)
Personnel costs € ( 87,740) ( 95,788) ( 115,484)
Subcontracting ( 160,076) ( 82,997) ( 61,192)
Disposables and lab fees and premises costs ( 17,629) ( 18,083) ( 19,529)
Depreciation, amortization and impairment ( 35,378) ( 22,254) ( 51,493)
Professional fees ( 15,949) ( 9,272) ( 9,316)
Other operating expenses ( 18,687) ( 12,900) ( 12,783)
Total R& D expenses € ( 335,459) ( 241,294) ( 269,797)
The table below summarizes our research and development expenses for the years ended December 31, 2024, 2023 and 2022, broken down by program.
Year ended December 31,
2024
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)
Ziritaxestat program € - - ( 1,096)
SIKi program ( 18,400) ( 18,900) ( 47,727)
TYK2 program on GLPG3667 ( 34,965) ( 31,289) ( 24,467)
Cell therapy programs in oncology ( 170,998) ( 82,218) ( 29,999)
Other discovery programs ( 111,096) ( 108,887) ( 166,507)
Total R& D expenses € ( 335,459) ( 241,294) ( 269,797)
SALES AND MARKETING EXPENSES
The following table summarizes the sales and marketing expenses for the years ended December 31, 2024, 2023 and 2022.
Year ended December 31,
2024
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)
Personnel costs € ( 6,561) ( 2,997) ( 1,693)
Depreciation and impairment ( 4,475) ( 113) ( 59)
External outsourcing costs ( 2,813) ( 1